Hipertensión arterial y diabetes mellitus

ANALES DEL SISTEMA SANITARIO DE NAVARRA

Suplemento 4

Hipertensión arterial y diabetes mellitus

J.J. Barbería

Sección de Endocrinología. Hospital de Navarra. Pamplona.

BIBLIOGRAFÍA

1. Amos AF, McCarty DJ, Zimmet P. The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the year 2010. Diabetic Med 1997; 14: S7-S85.

2. Tamayo-Marco B, Faure Nogueras E, Roche Asensio MT, Rubio-Calvo E, Sánchez Ortiz E., Salvador Olivan JA. Prevalence of diabetes and impaired glucose tolerance in Aragon, Spain. Diabetes Care 1997; 20: 534-536

3. Zimmet P, Alberti KGMM. The changing face of macrovascular disease in non-insulin- dependent diabetes mellitus: an epidemic in progress. Diabetes and the Heart. Lancet 1997; 350 (Suppl I):1-32

4. Howard BV. Risk factors for cardiovascular disease in individuals with diabetes. The Strong Heart Study. Acta Diabetol 1996; 33: 280-184.

5. Bretzel RG. Can we further slow the progression to end-stage renal disease in diabetes hypertensive patients? Hypertens 1997 (Suppl) 15: 583-588.

6. Kannel WB, Wilson PW. Comparison of risk profiles for cardiovascular events: its implication for prevention. Adv Intern Med 1997; 42: 39-66.

7. Aranz Pacheco C, Raskin P, Hypertension in Diabetes Mellitus. Endocrinol Metab Clin North Am 1996; 25: 401-423.

8. Haffner SM, Miettinen H. Insulin implications for type 2 diabetes and coronary heart disease. Am J Med 1997; 103: 152-162

9. Poulsen PL, Hansen KW, Mogensen CE. Ambulatory blood pressure in the transition from normo to microalbuminuria. Diabetes 1994; 43: 1248-1253.

10. Nosadini R, Brocco E. Relationship among microalbuminuria, insulin resistence and renal-cardiac complications in insulin and non insulin dependent diabetes. Exp. Clin Endocrinol Diabetes 1997;105 (Suppl 2):1-7

. 11. Feldt-Rasmunssen B, Mathiesen ER, Deckert T. Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type 1 diabetes mellitus. Diabetologia 1987; 30: 610-617.

12. Reaven GM. Role of the insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.

13. Hanefeld M. Leonhardt W The Metabolic Syndrome. Hanefeld M, Leonhardt W (Eds.). Gustav Fisher Verlag Jena. Germany. 1997. Bayer.

14. Ward KD, Sparrow D, Landsberg L, Young JB, Weiss ST. The influence of obesity, insulin and sympathetic nervous system activity on blood pressure. Clin Res 1993; 41: 168-171.

15. Petrie JR, Uede SH, Webb DJ, Elliot HL, Connell JMC. Endothelial nitric oxide production and insulin resistance syndrome. Circulation 1996; 93: 1331-1333.

16. Vague JI, Thomson SG, Jespersen J, Collen D, Alessi MP, Vague P et al. Involvement of hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Atheroscler. Thromb 1993; 13: 1865-1873.

17. Lee J, Sparrow D, Vokonas PS, Landberg L, Weiss ST. Uric acid and coronary heart disease risk:Evidence for a role of uric acid in the obesity-insulin resistance syndrome. Am J Epidemiol 1995; 142: 288-294. 18. González Maqueda Y. Hipertensión arterial y Diabetes. Rev Esp Cardiol 1997; 50 (Supl. 4) 33-48.

19. Esmatges E. Goicolea I, Cacho L, De Pablos PL, Rodríguez Erdozain MR, Roche MJ et al. Nefropatía diabética en la diabetes mellitus tipo 2: prevalencia en España. Grupo de Trabajo de Nefropatía Diabética de la Sociedad Española de Diabetes. Adv Diabetol 1997; 13: 29-35.

20. Olivarius NF, Andreasen AH, Keiding N, Mogensen CE. Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients. Denmark Diabetollogia 1993; 36: 1007-1016.

21. Marre M, Girault A, Vasmant D. Prevalence de la microalbuminuria chez les diabetiques de type 2 francais suivis par leur medicine generalist. Diabet Metabol 1995; 21: 34-40

22. Patrick AW, Leslie PJ, Clarke BF, Frier BM. The natural history and associations with microalbuminuria in type 2 diabetes diuring the first year after diagnosis. Diabetic Med 1990; 7: 902-908.

23. Unsipute M, Siitonen O, Penttilä I, Aro A, Pyöraläk. Proteinuria in newly diagnosed type 2 diabetic patients. Diabetes Care 1987; 10: 191-194.

24. Standl E, Stiegler H, Microalbuminuria in a random cohort of recently diagnosed type 2 diabetic patients living in the Greater Munich Area. Diabetologia 1993; 36: 1017-1020.

25. UK Prospective Diabetes Study Group. Urinary albumin excretion over 3 years in diet-treated type 2 diabetic patient and association with hypertension, hyperglucemia and hypertriglyceridemia. Diabetologia 1993; 36: 1021-1029

26. Consensus Development Conference. Treatment of Hypertension in Diabetes: Diabetes Care 1996; 19 (Suppl 1): S107-S112.

27. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The fifht report of the JNC-V. Arch Intern Med 1993; 153: 154-183

28. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parvigg HH, Passa P et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-1084.

29. Documento de Consenso sobre pautas de detección de la nefropatía diabética en España. Av Diabetol 1997; 13: 92-98.v 30. Sawicki PT, Heise T, Berger M. Antihypertensive treatment and mortality in diabetic patients. What is the evidence? Diabetologia 1997; 40: S134-S137.

31. Report of The Expert Committe on The Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.v 32. Borch-Johnsen K, N_gaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T et al. Is diabetic nephropathy an inherited complication? Kidney Int 1992; 41: 719-722.

33. Bjorck S, Blohme G, Sylven C, Mulec H. Delection insertion polimorphism of the angiotensine converting enzyme gene and progression of diabetic nephropathy. Nephrol Dial Transplant 1997; 12 (Suppl 2): 67-70.

34. Honeyman M, Wasserfall C, Nerup J, Rossini A. Prediction and prevention of IDDM. Diabetologia 1997; 40: B58-B61.

35. Winter WE, House DV, Schatz D. Pharmacological approaches to the prevention of autoinmune diabetes. Drugs 1997; 53: 943-956.

36. Toeller M, Klischan A. Nutritional intake of 2868 IDDM patients from 30 centres in Europe. Eurodiab Iddm Complications Study Group. Diabetologia 1996; 39: 929-939.

37. Bakris GL, Weir MR. Salt intake, and reductions in arterial pressure and proteinuria. Is there a direct link? Am J Hypertens 1996; 9: S200-S206.

38. Meeking DR, Cavan DA. Alcohol ingestion and glycaemic control in patients with insulin-dependent diabetes mellitus. Diabet Med 1997; 14: 279-283.

39. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.

40. Mogensen CE. How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes 1997; 46 (Suppl 2): S104-S111.

41. Meigs JB, Singer DE, Sullivan LM, Dukas DA, D´Agostino RB, Nathan DM. Metabolic control and prevalent cardiovascular disease in NIDDM: The NIDDM Patient Outcome Research Team. Am J Med 1997; 102: 38-47.

42. Teuscher AV, Weidmann PV. Requirements for antihypertensive therapy in diabetic patients: metabolic aspects. J Hypertens 1997 (Suppl 15): S67-S75.

43. Lapuz MH Diabetic Nephropathy. Med Clin North Amer 1997; 81: 679-688.

44. Backvis G, White D. Effects on ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. J Hum Hypertens 1997; 11: 35-38.

45. The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996; 39: 587-593.

46. Ravid M, Savin H, Jutrin Y, Bental T, Katz B, Lishner M et al. Long-term stabilizing effect on angiotensine converting enzyme inhibition on plasma cretinine and on proteinuria in normotensive type 2 diabetic patients. Ann Intern Med 1993; 118: 577-581.

47. Mathiesen ER, Hommel E, Smith V. Efficacy of captopril in normotensive patients with microalbuminuria: 8 years follow-up. Diabetologia 1995; 38: (Suppl 1): A46.

48. Ravid M, Lang R, Rachman R, Lishner M. Long-term renoprotective effect of angiotensine-converting enzyme inhibition in NIDDM: A 7-year follow-up study. Arch Intern Med 1996; 156: 286-289.

49. THE EUCLID STUDY GROUP. Ramdomiced placebo-controled trial of lisinopril in normotensive patients with IDDM and normoalbuminuria o microalbuminuria. Lancet 1997; 349: 1787-1792.

50. Baba T, Neugbauer S, Watanabe T. Diabetic nephropathy: Its relationship to hypertension and means of pharmacological intervention. Drugs 1997; 54: 197-234.

51. Nielsen S, Dollerup J, Nielsen B, Jensen HA, Mogensen CE. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controled 3 months study. Nephrol Dial Transplant 1997; 12 (Suppl 2): 19-23.